Ten seconds to set up. Two blinks to speak. And a price tag roughly one-tenth what the market leaders charge.
That's the pitch from Neural Drive, a Singapore startup barely a year old that has begun testing a low-cost brain-computer interface at Tan Tock Seng Hospital, one of the city-state's largest public medical centers. The April launch of the speech restoration trial, reported by industry tracker BCIIntel, comes at a curious moment: the same month Neuralink closed a $650 million funding round, part of more than $1 billion that poured into the brain-computer interface sector in the first quarter of 2026 alone.
Most of that capital is chasing surgical implants and research-grade systems priced well into five figures. Neural Drive's founders—Mohammed HK, Raymond Loong Ng, and Kaushik Manian—are betting there's a different opening. They're aiming at paralysis, stroke, and ALS patients who need to communicate now, not after years of clinical trials and FDA approvals. The device, which Neural Drive says costs around SGD 2,500 (roughly $1,850), sits on the head like a gaming headset and tracks blinks to activate pre-programmed phrases. Think less sci-fi brain surgery, more souped-up accessibility tech.
Whether that's enough to compete in a suddenly crowded field remains to be seen.
The Billion-Dollar Context
The timing feels deliberate. Neuralink's April funding wasn't an outlier. Science Corp, led by former Neuralink president Max Hodak, raised $230 million in March. Merge Labs—co-founded by OpenAI's Sam Altman—emerged from stealth in January with roughly $250 million already in the bank. Synchron, another player in the implantable space, has been running U.S. trials since 2021.
All of which makes Neural Drive's hospital collaboration notable, if not exactly groundbreaking. The company was incorporated in March 2025, according to Singapore filings, which means it went from formation to clinical trial in about thirteen months. Its marketing materials display logos from the National Healthcare Group, Tan Tock Seng, and Khoo Teck Puat Hospital, though no formal partnership agreements beyond the trial itself have been publicly disclosed. The exact parameters of the TTSH study—patient numbers, trial endpoints, completion dates—have not been publicly announced.
What Neural Drive has disclosed is self-reported user data that lacks independent verification. The company claims 368 people have tested the system, with its blink-selection interface achieving 98% command accuracy. A more experimental feature—"silent speech" decoding via vocal cord micro-vibrations—reportedly hits 92% accuracy for ten unique thought commands, initiated in under 45 seconds. Peer-reviewed validation for any of these figures does not yet exist.
Still, the price comparison is striking. Neural Drive's website lays out a competitive landscape: Emotiv headsets at SGD 3,000, Zeto systems at SGD 12,000, Neurostyle at SGD 15,000, Tobii Dynavox eye-tracking at SGD 24,399. At SGD 2,500, Neural Drive undercuts them all—though the company has elsewhere referenced a $500 price point without clarifying whether that reflects developer kits, earlier pricing, or a different market tier altogether.
Hackathons, Prizes, and Opacity
The funding picture is muddy. Neural Drive's profile on the Startup Battlefield platform states "$200K funding secured" without breaking down the funding into specific categories such as debt, equity, or grants. Founder bios reference self-reported figures of roughly SGD 120,000 from China-based competitions, a "Baby Shark Fund" grant from Singapore University of Technology and Design in October 2025, and reported wins approaching $200,000 from Plug and Play Asia and Harvard hackathons. None of these amounts have been independently confirmed by third-party outlets.
Raymond Loong Ng, the 21-year-old chief AI officer, was profiled by The Straits Times in February for accessibility tech work. The article noted his startups had received "more than $200,000 in funding" from competitions and grants—a figure echoed in a June feature by Singapore Global Network. Whether that $200,000 spans multiple ventures or applies solely to Neural Drive is unclear.
The company's LinkedIn, updated sometime in May or June, states Neural Drive is "currently raising $450,000 to scale from 10 to 100 unique thought commands and launch our Kickstarter campaign with 1,000 developer kits." No Kickstarter page is live. No lead investor has been named. No term sheet details have surfaced.
Which brings us to an awkward detail: no public filing, press release, or credible media report confirms that Neural Drive has closed a formal seed round. If the company has secured institutional equity capital beyond competition winnings and grants, it's kept that news remarkably quiet.
The Regulatory Puzzle
Then there's the matter of regulatory approval—or lack thereof. Neural Drive's own websites offer contradictory claims. One marketing page states "HSA Class A (Q1 2026)," referring to Singapore's Health Sciences Authority. Another says "HSA Class B pathway (Q1 2026) Projection." Neither provides an HSA registration number. Class A devices carry the lowest risk classification in Singapore; Class B requires more rigorous controls. The inconsistency suggests Neural Drive is still figuring out where it sits in the regulatory hierarchy.
That ambiguity isn't unusual for early-stage medical device startups, particularly those operating in the gray zone between consumer electronics and clinical tools. But it complicates the company's pitch to hospitals and healthcare providers who need clear compliance pathways before they can deploy new technologies at scale.
Betting on the Gap
Neural Drive's core argument is simple: the brain-computer interface market has focused so intensely on high-end solutions—implants that require neurosurgery, research-grade EEG systems that cost tens of thousands—that it's ignored a vast middle tier of patients and institutions that can't afford any of it. The World Health Organization estimated in 2022 that 1.3 billion people globally live with significant disabilities. Neural Drive sees that as its addressable market, though converting an epidemiological baseline into paying customers is another matter.
The question is whether a SGD 2,500 headset can deliver outcomes that matter clinically. The TTSH trial might offer early signals, assuming Neural Drive eventually releases data. But in a sector where Neuralink is expanding human trials with implanted electrodes capable of fine motor control, and where Merge Labs is building AI-integrated interfaces with backing from one of the world's most influential technologists, Neural Drive's approach looks less like cutting-edge innovation and more like accessibility engineering—important, perhaps, but not exactly the stuff of venture capital fever dreams.
Which may be the point. If the goal is to deploy in public hospitals across Southeast Asia, or to sell direct to disability service providers in markets where $25,000 eye-tracking systems are non-starters, then affordability becomes the product. The technology just has to be good enough.
What Comes Next
For now, Neural Drive remains a clinical experiment with a pricing argument. The founders say the $450,000 they're raising will expand the device's command library tenfold and fund a developer kit campaign aimed at building a community of third-party builders. Whether that happens depends on data Neural Drive hasn't yet published, regulatory clarity it hasn't yet achieved, and capital it hasn't yet secured.
If the TTSH trial yields favorable results—and if the company can thread the regulatory needle without getting caught in conflicting claims—Neural Drive could position itself as the accessible entry point into a technology that has, until now, been the domain of billionaires and research universities. Public hospitals have watched capital flood the brain-computer interface sector without seeing many deployable products they can actually afford.
Neural Drive is betting that gap is big enough to build a company around—though whether it can become profitable remains an open question.
